Brenus Pharma Secures $12 Million in Latest Series A Extension Funding Round

Brenus Pharma secured $12 million in its latest Series A Extension, adding another data point to the Healthcare & Life Sciences funding market.

Brenus Pharma Raises $12 million in Funding

Brenus Pharma raised EUR 11M (~$12M) in a Series A extension to advance immuno-oncology pipeline.

Investors Behind the Funding

The round was backed by undisclosed investors. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Brenus Pharma operates in Healthcare & Life Sciences. Biotech Series A extensions remain active in Europe, with immuno-oncology drawing continued capital.

Strategic Use of Funds

Advance clinical pipeline

Looking Ahead

Brenus Pharma continues to attract investor attention following its latest financing.

Source reference: original announcement/article.